Handrean Soran Selected Research

LDL glycated lipoproteins

1/2016	Diabetic dyslipidaemia.
8/2011	Susceptibility of LDL and its subfractions to glycation.
10/2010	Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes.
1/2009	Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Handrean Soran Research Topics

Disease

29	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 11/2009
22	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2006
17	Obesity 01/2022 - 07/2013
14	Atherosclerosis 01/2022 - 08/2008
12	Weight Loss (Weight Reduction) 01/2022 - 01/2013
10	Inflammation (Inflammations) 03/2022 - 07/2013
9	Homozygous Familial Hypercholesterolemia 01/2022 - 05/2015
9	Morbid Obesity 03/2021 - 09/2014
8	Dyslipidemias (Dyslipidemia) 07/2021 - 01/2012
7	Peripheral Nervous System Diseases (PNS Diseases) 07/2022 - 01/2018
7	Insulin Resistance 01/2022 - 07/2013
7	Diabetes Mellitus 01/2018 - 08/2008
6	Pancreatitis 01/2022 - 01/2017
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 10/2010
6	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 01/2012
5	Hypertriglyceridemia 07/2022 - 01/2016
5	Diabetic Neuropathies (Diabetic Neuropathy) 03/2021 - 01/2021
4	Myocardial Infarction 01/2022 - 11/2009
4	Hypertension (High Blood Pressure) 01/2020 - 08/2008
4	Inborn Genetic Diseases (Disease, Hereditary) 01/2019 - 11/2016
4	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 01/2019 - 01/2017
3	Infections 01/2021 - 08/2015
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 01/2006
3	COVID-19 01/2021 - 11/2020
3	Injection Site Reaction 01/2019 - 01/2012
3	Weight Gain 01/2013 - 01/2006
2	Necrosis 01/2022 - 01/2021
2	Hypercholesterolemia 01/2022 - 01/2012
2	Thyrotoxicosis 01/2021 - 09/2002
2	Small Fiber Neuropathy 01/2021 - 01/2019
2	Niemann-Pick Diseases (Niemann Pick Disease) 01/2021 - 09/2015
2	Costello Syndrome 07/2018 - 01/2018
2	Atrial Fibrillation 01/2018 - 01/2012
2	Body Weight (Weight, Body) 11/2017 - 01/2017
2	Stroke (Strokes) 01/2017 - 11/2009
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2015 - 05/2013
2	Coronary Disease (Coronary Heart Disease) 08/2015 - 01/2009
2	Flushing 06/2012 - 01/2012

Drug/Important Bio-Agent (IBA)

24	oxidized low density lipoproteinIBA 01/2022 - 08/2008
21	LipidsIBA 07/2022 - 01/2012
21	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2010
15	Lipoproteins (Lipoprotein)IBA 01/2022 - 10/2010
15	LDL CholesterolIBA 01/2022 - 07/2014
14	CholesterolIBA 01/2022 - 09/2015
12	Triglycerides (Triacylglycerol)IBA 07/2022 - 07/2014
12	HDL CholesterolIBA 01/2021 - 08/2012
6	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022 - 05/2015
6	HDL LipoproteinsIBA 01/2022 - 09/2014
6	ApolipoproteinsIBA 01/2021 - 08/2011
6	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2006
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
5	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 05/2013
4	Apolipoproteins B (ApoB)IBA 01/2022 - 10/2010
4	Proprotein Convertase 9IBA 01/2021 - 07/2017
4	Niacin (Nicotinic Acid)FDA LinkGeneric 11/2020 - 01/2012
4	Pharmaceutical PreparationsIBA 11/2019 - 06/2016
4	Insulin (Novolin)FDA Link 01/2019 - 01/2006
4	LDL glycated lipoproteinsIBA 01/2016 - 01/2009
3	C-Reactive ProteinIBA 01/2022 - 01/2015
3	PCSK9 InhibitorsIBA 01/2022 - 12/2016
3	Lipoprotein(a)IBA 03/2021 - 08/2014
3	AcidsIBA 01/2021 - 09/2015
3	BMS201038IBA 11/2020 - 12/2016
3	Bile Acids and Salts (Bile Acids)IBA 11/2020 - 12/2016
3	ISIS 304801IBA 11/2020 - 07/2018
3	evolocumabIBA 01/2020 - 07/2017
3	CytokinesIBA 01/2019 - 07/2013
3	AdiponectinIBA 01/2017 - 07/2013
3	MK-0524IBA 09/2015 - 01/2012
2	diazonaphthalenedisulfonic acid (NDS)IBA 07/2022 - 01/2021
2	Aryldialkylphosphatase (Paraoxonase)IBA 01/2022 - 08/2009
2	AntibodiesIBA 01/2022 - 09/2015
2	LDL Receptors (LDL Receptor)IBA 01/2022 - 01/2017
2	NAD (NADH)IBA 01/2021 - 01/2018
2	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2021 - 09/2015
2	olipudase alfaIBA 01/2021 - 09/2015
2	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2018
2	neodymium pyrocatechin disulfonate (NPD)IBA 01/2021 - 09/2015
2	Ezetimibe (Zetia)FDA Link 11/2020 - 12/2016
2	Fibric Acids (Fibrates)IBA 11/2020 - 07/2014
2	Monoclonal AntibodiesIBA 11/2020 - 12/2015
2	Hormones (Hormone)IBA 01/2020 - 01/2014
2	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2019 - 01/2017
2	alirocumabIBA 07/2017 - 12/2015
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2017 - 09/2014
2	AntioxidantsIBA 09/2015 - 09/2014
2	AdipokinesIBA 01/2015 - 07/2013
2	low density lipoprotein inhibitorIBA 03/2013 - 10/2010
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2012 - 08/2008
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 06/2010 - 11/2009
1	Hypoglycemic Agents (Hypoglycemics)IBA 03/2022
1	HMGB1 Protein (HMG1)IBA 03/2022
1	AutoantibodiesIBA 01/2022
1	Oxidoreductases (Dehydrogenase)IBA 01/2022

Therapy/Procedure

27	Therapeutics 01/2022 - 01/2006
17	Bariatric Surgery 01/2022 - 07/2013
6	Blood Component Removal (Apheresis) 02/2020 - 11/2016
3	Drug Therapy (Chemotherapy) 01/2021 - 12/2016
2	Gastric Bypass (Roux-en-Y Gastric Bypass) 02/2021 - 01/2021
2	Enzyme Replacement Therapy 01/2021 - 09/2015